Last reviewed · How we verify

Generalized pustular psoriasis — Treatment Landscape & Competitive Intelligence

Generalized pustular psoriasis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Generalized pustular psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Spevigo SPESOLIMAB Boehringer Ingelheim Pharmaceuticals Inc Interleukin-36 Receptor Antagonist [EPC] Interleukin-1 receptor-like 2 2022-01-01
SPEVIGO SPESOLIMAB-SBZO BOEHRINGER INGELHEIM PHARMACEUTICALS INC Interleukin-36 Receptor Antagonist [EPC] Interleukin-1 receptor-like 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. BOEHRINGER INGELHEIM PHARMACEUTICALS INC · 1 drug in Generalized pustular psoriasis
  2. Boehringer Ingelheim Pharmaceuticals Inc · 1 drug in Generalized pustular psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Generalized pustular psoriasis:

Cite this brief

Drug Landscape (2026). Generalized pustular psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/generalized-pustular-psoriasis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing